Journal article
Triple-negative breast cancer: Making the most of a misnomer
N Mccarthy, G Mitchell, M Bilous, N Wilcken, GJ Lindeman
Asia Pacific Journal of Clinical Oncology | WILEY | Published : 2012
Abstract
Triple-negative breast cancer (TNBC) is defined by its lack of (or minimal) estrogen receptor and progesterone receptor expression, together with the absence of human epidermal growth factor receptor 2 overexpression or gene amplification. It can be a particularly aggressive form of breast cancer, often characterized by early systemic relapse. This subtype, absent from traditional pathology classifications, has quietly crept into the oncologist's lexicon over the last decade and aroused considerable research interest. Based on tumor pathology, immunohistochemistry and gene profiling studies, TNBC is likely to represent a heterogeneous mix of breast cancer subtypes. This observation will have..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This review was written by the authors following a workshop on TNBC, carried out with financial support from Sanofi-Australia. The authors thank Scius Solutions for editorial assistance in the preparation of this manuscript; whose contribution was funded by Sanofi-Australia. GJL is supported by a National Health and Medical Research Council Research Fellowship (637307).